Nuvalent Inc. (NUVL)
NASDAQ: NUVL
· Real-Time Price · USD
76.39
-0.36 (-0.47%)
At close: May 01, 2025, 3:59 PM
76.23
-0.21%
After-hours: May 01, 2025, 04:09 PM EDT
-0.47% (1D)
| Bid | 72.45 |
| Market Cap | 5.47B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -260.76M |
| EPS (ttm) | -3.93 |
| PE Ratio (ttm) | -19.44 |
| Forward PE | -15.73 |
| Analyst | Buy |
| Ask | 78.48 |
| Volume | 417,693 |
| Avg. Volume (20D) | 561,672 |
| Open | 76.65 |
| Previous Close | 76.75 |
| Day's Range | 75.23 - 78.54 |
| 52-Week Range | 55.53 - 113.51 |
| Beta | 1.43 |
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 142
Stock Exchange NASDAQ
Ticker Symbol NUVL
Website https://www.nuvalent.com
Analyst Forecast
According to 8 analyst ratings, the average rating for NUVL stock is "Buy." The 12-month stock price forecast is $112.5, which is an increase of 47.27% from the latest price.
Stock Forecasts7 months ago
-6.61%
Nuvalent shares are trading lower after the compan...
Unlock content with
Pro Subscription
7 months ago
+28.27%
Nuvalent shares are trading higher after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.
